
LogicBio Therapeutics LOGC
Quartalsbericht 2022-Q3
hinzugefügt 14.11.2022
LogicBio Therapeutics Zahlungsmittel 2011-2026 | LOGC
Zahlungsmittel Jährlich LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 53.5 M | 70.1 M | 33.1 M | 80.9 M | 24.6 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 80.9 M | 24.6 M | 52.4 M |
Zahlungsmittel Vierteljährlich LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 30.8 M | 38.8 M | 42.7 M | 53.5 M | 59.6 M | 68.1 M | 63.9 M | 70.1 M | 70.1 M | 70.1 M | 70.1 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M | 24.6 M | 24.6 M | - | - | 1.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 80.9 M | 1.73 M | 52 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
129 M | $ 3.44 | -4.32 % | $ 1.03 B | ||
|
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
ADMA Biologics
ADMA
|
87.6 M | $ 15.36 | -2.17 % | $ 3.66 B | ||
|
Cellectis S.A.
CLLS
|
143 M | $ 3.53 | -3.54 % | $ 116 M | ||
|
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | ||
|
Apellis Pharmaceuticals
APLS
|
466 M | $ 20.28 | 0.65 % | $ 2.56 B | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
830 K | - | -19.68 % | $ 18.4 M | ||
|
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | ||
|
Aptorum Group Limited
APM
|
3.5 M | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.51 | 1.35 % | $ 385 M | ||
|
China SXT Pharmaceuticals
SXTC
|
13.4 M | $ 2.01 | -1.36 % | $ 2.86 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
6.95 M | $ 0.67 | 7.08 % | $ 624 K | ||
|
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | ||
|
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | ||
|
Anika Therapeutics
ANIK
|
72.9 M | $ 14.05 | -1.44 % | $ 206 M | ||
|
ANI Pharmaceuticals
ANIP
|
145 M | $ 74.36 | -1.64 % | $ 1.44 B | ||
|
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | ||
|
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | ||
|
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | ||
|
AVEO Pharmaceuticals
AVEO
|
70.5 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
323 M | $ 162.43 | 0.6 % | $ 8.08 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
105 M | $ 8.49 | -0.18 % | $ 1.75 B | ||
|
BridgeBio Pharma
BBIO
|
570 M | $ 65.66 | -0.78 % | $ 12.6 B | ||
|
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
187 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B | ||
|
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | ||
|
BioLineRx Ltd.
BLRX
|
10.4 M | $ 2.69 | -0.74 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.31 B | $ 61.3 | 1.21 % | $ 11.8 B | ||
|
Burford Capital Limited
BUR
|
322 M | $ 7.79 | -5.75 % | $ 1.28 B | ||
|
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B |